Novartis Investigative Site

Siegen 57076

0 studies enrolling now · 17 studies all time

What they study most

Acute Myeloid Leukemia (AML), Alzheimers Disease, Atherosclerosis, Attention Deficit/Hyperactivity Disorder, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Hypertension, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Scelrosis, Relapsing Multiple Sclerosis

Studies at this site

• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab — Completed
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Efficacy and Safety of LCZ696A in Patients With Essential Hypertension — Completed
• Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder — Completed
• Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD) — Completed